|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2004-4-20
|
|
pubmed:abstractText |
The immune system plays a critical role in the development and pathogenesis of actinic keratosis (AK). Imiquimod has been shown to stimulate the cutaneous immune response and be effective for the treatment of nonmelanoma skin cancers.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0190-9622
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
50
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
714-21
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15097955-Adjuvants, Immunologic,
pubmed-meshheading:15097955-Adult,
pubmed-meshheading:15097955-Aged,
pubmed-meshheading:15097955-Aged, 80 and over,
pubmed-meshheading:15097955-Aminoquinolines,
pubmed-meshheading:15097955-Double-Blind Method,
pubmed-meshheading:15097955-Female,
pubmed-meshheading:15097955-Humans,
pubmed-meshheading:15097955-Keratosis,
pubmed-meshheading:15097955-Male,
pubmed-meshheading:15097955-Middle Aged,
pubmed-meshheading:15097955-Ointments,
pubmed-meshheading:15097955-Pharmaceutical Vehicles,
pubmed-meshheading:15097955-Photosensitivity Disorders,
pubmed-meshheading:15097955-Ultraviolet Rays
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.
|
|
pubmed:affiliation |
Department of Dermatology, Mount Sinai School of Medicine, New York, New York 10029-6574, USA. Lebwohl@aol.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
